ArticleThe Journal of infectious diseases2016
A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2018Guideline
- Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.Journal of viral hepatitis · 2019Trial
- Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Divergent hepatitis B neutralizing antibody trajectories after spontaneous control in people with and without HIV.Research square · 2026Article
- Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults.Hepatology communications · 2026Article
- Serological evidence of hepatitis B virus exposure and vaccination coverage trends in health sciences students in Albania.World journal of virology · 2026Article
- Prevalence of hepatitis B surface antibodies and hepatitis B exposure in Belgium: results from a nationwide population-based serosurvey.BMC infectious diseases · 2026Article
- Article
- Article
- Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective.NPJ vaccines · 2025Article
- Persistence of Anti-HB Antibodies in Healthcare Trainees: The Impact of Childhood Versus Adolescent Vaccination.Vaccines · 2025Article
- Immune response and associated factors to Hepatitis B vaccination among children under five attending care at mulago hospital.BMC pediatrics · 2025Article
- Article
- Health and economic impact of hepatitis B vaccination in the national immunization program in Belarus, Georgia, Kyrgyzstan, Republic of Moldova, Turkmenistan and Uzbekistan-a modelling study.Frontiers in public health · 2025Article
- High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy.Digestive diseases and sciences · 2024Article
- Good Practices and Initiatives for the Control and Elimination of Hepatitis B in the World: A Scoping Review.Cureus · 2024Article
- Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis.Tropical medicine and health · 2024Review
- Prevalence of vaccine-derived hepatitis B surface antibodies in children and adolescents in Germany: results from a population-based survey, 2014-2017.BMC infectious diseases · 2024Article
- Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLong-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermined.
methodsWe recruited persons from a cohort vaccinated with plasma-derived hepatitis B vaccine in 1981 who have been followed periodically since. We performed serological testing for anti-HBs and microRNA-155 and assessed HBV-specific T-cell responses by enzyme-linked immunospot and cytometric bead array. Study subgroups were defined 32 years after vaccination as having an anti-HBs level of either ≥10 mIU/mL (group 1; n = 13) or <10 mIU/mL (group 2; n = 31).
resultsAll 44 participants, regardless of anti-HBs level, tested positive for tumor necrosis factor α, interleukin 10, or interleukin 6 production by HBV surface antigen-specific T cells. The frequency of natural killer T cells correlated with the level of anti-HBs (P = .008). The proportion of participants who demonstrated T-cell responses to HBV core antigen varied among the cytokines measured, suggesting some natural exposure to HBV in the study group. No participant had evidence of breakthrough HBV infection.
conclusionsEvidence of long-lasting cellular immunity, regardless of anti-HBs level, suggests that protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 32 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.